Artelo Biosciences Inc (ARTL)

$1.24 -0.08 (-6.06%)
Market Cap 2.67M
Revenue (ttm) 0.00
Net Income (ttm) -9.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 20,300
Avg Vol 75,208
Day's Range N/A - N/A
Shares Out 2.02M
Stochastic %K 35%
Beta 1.13
Analysts Hold
Price Target $18.00

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumat...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 925 7049
Address:
505 Lomas Santa Fe, Suite 160, Solana Beach, United States
BillionerOfKing
BillionerOfKing Feb. 23 at 12:05 PM
$ARTL Current Stock Price: $1.32
0 · Reply
Foamius2
Foamius2 Feb. 20 at 6:33 PM
$ARTL Gorgas sucks moose caulk
0 · Reply
ttesty
ttesty Feb. 20 at 3:29 PM
$ENSC reminder... $ARTL is UP UP UP
0 · Reply
CapitalProvenance
CapitalProvenance Feb. 20 at 2:06 PM
$ARTL Artelo Biosciences develops cannabinoid-based therapeutics targeting inflammatory diseases. Valuation is driven entirely by clinical milestones rather than revenue. Cash runway and trial execution define downside risk.
1 · Reply
Ruxin31
Ruxin31 Feb. 19 at 8:35 PM
$ARTL grabbed some here
0 · Reply
TinyTiger19
TinyTiger19 Feb. 19 at 7:23 PM
$ALLR $TMDE $ARTL $CBIO ~~~
0 · Reply
ttesty
ttesty Feb. 19 at 4:23 PM
$ENSC ..... $ARTL is now UP UP!
0 · Reply
TammieHumphrey648
TammieHumphrey648 Feb. 18 at 1:29 PM
$ARTL Consumer products microcap with execution risk.
0 · Reply
_EmproX
_EmproX Feb. 17 at 2:36 PM
$FMST $XAIR $NDRA $ARTL =*=**
0 · Reply
CeaseNDesist
CeaseNDesist Feb. 12 at 12:33 AM
$ARTL is this thing ever going to do anything??
1 · Reply
Latest News on ARTL
Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Dec 23, 2025, 9:00 AM EST - 2 months ago

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 8:00 AM EST - 3 months ago

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Nov 4, 2025, 8:30 AM EST - 3 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Oct 27, 2025, 8:00 AM EDT - 4 months ago

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Oct 15, 2025, 9:15 AM EDT - 4 months ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Oct 1, 2025, 4:05 PM EDT - 5 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 30, 2025, 8:30 AM EDT - 5 months ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025, 7:15 PM EDT - 5 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 29, 2025, 8:30 AM EDT - 5 months ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 5, 2025, 4:05 PM EDT - 6 months ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 4, 2025, 8:37 AM EDT - 6 months ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 3, 2025, 11:33 AM EDT - 6 months ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Sep 3, 2025, 8:45 AM EDT - 6 months ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Aug 25, 2025, 7:55 AM EDT - 6 months ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 6 months ago

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 11, 2025, 9:15 AM EDT - 7 months ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 4, 2025, 7:30 AM EDT - 7 months ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Aug 1, 2025, 7:45 AM EDT - 7 months ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 9, 2025, 7:50 AM EDT - 8 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Analyst See It As An Emerging Biotech

Jul 8, 2025, 3:06 PM EDT - 8 months ago

Artelo Biosciences Analyst See It As An Emerging Biotech

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jul 7, 2025, 7:45 AM EDT - 8 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 30, 2025, 7:45 AM EDT - 8 months ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 26, 2025, 8:00 AM EDT - 8 months ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Artelo Biosciences Announces Reverse Stock Split

Jun 11, 2025, 8:30 AM EDT - 9 months ago

Artelo Biosciences Announces Reverse Stock Split

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 5, 2025, 9:00 AM EDT - 9 months ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Jun 2, 2025, 9:00 AM EDT - 9 months ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 10 months ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Apr 28, 2025, 8:45 AM EDT - 10 months ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Mar 31, 2025, 8:30 AM EDT - 11 months ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Feb 14, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Feb 11, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Jan 13, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Dec 9, 2024, 9:15 AM EST - 1 year ago

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Nov 18, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Nov 13, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Nov 5, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Oct 9, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Jul 15, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Jul 3, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

May 29, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

May 10, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Apr 23, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Apr 22, 2024, 8:30 AM EDT - 2 years ago

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

Mar 12, 2024, 9:15 AM EDT - 2 years ago

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

BillionerOfKing
BillionerOfKing Feb. 23 at 12:05 PM
$ARTL Current Stock Price: $1.32
0 · Reply
Foamius2
Foamius2 Feb. 20 at 6:33 PM
$ARTL Gorgas sucks moose caulk
0 · Reply
ttesty
ttesty Feb. 20 at 3:29 PM
$ENSC reminder... $ARTL is UP UP UP
0 · Reply
CapitalProvenance
CapitalProvenance Feb. 20 at 2:06 PM
$ARTL Artelo Biosciences develops cannabinoid-based therapeutics targeting inflammatory diseases. Valuation is driven entirely by clinical milestones rather than revenue. Cash runway and trial execution define downside risk.
1 · Reply
Ruxin31
Ruxin31 Feb. 19 at 8:35 PM
$ARTL grabbed some here
0 · Reply
TinyTiger19
TinyTiger19 Feb. 19 at 7:23 PM
$ALLR $TMDE $ARTL $CBIO ~~~
0 · Reply
ttesty
ttesty Feb. 19 at 4:23 PM
$ENSC ..... $ARTL is now UP UP!
0 · Reply
TammieHumphrey648
TammieHumphrey648 Feb. 18 at 1:29 PM
$ARTL Consumer products microcap with execution risk.
0 · Reply
_EmproX
_EmproX Feb. 17 at 2:36 PM
$FMST $XAIR $NDRA $ARTL =*=**
0 · Reply
CeaseNDesist
CeaseNDesist Feb. 12 at 12:33 AM
$ARTL is this thing ever going to do anything??
1 · Reply
ShadowBreaker
ShadowBreaker Feb. 9 at 12:41 PM
$ARTL is an artificial intelligence or robotics company; the "ARTL" name suggests robotics, a field where commercialization and scaling are major hurdles.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 6 at 3:25 AM
$ARTL RSI: 31.17, MACD: -0.0365 Vol: 0.14, MA20: 1.63, MA50: 1.64 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ttesty
ttesty Feb. 5 at 4:40 PM
$ENSC was $0.50 for $PFE $ARTL buy. Now basically a door stop. Maybe less.
0 · Reply
PennyPrince7
PennyPrince7 Feb. 1 at 9:18 PM
$ARTL
0 · Reply
Aim977
Aim977 Jan. 30 at 5:56 PM
$ARTL so what was the meeting outcome
0 · Reply
ttesty
ttesty Jan. 29 at 6:21 PM
$ARTL is more viable than $ENSC anyway.
0 · Reply
aim97
aim97 Jan. 29 at 1:45 PM
$ARTL board meeting tomorrow. pump it fgs
0 · Reply
ttesty
ttesty Jan. 27 at 12:27 AM
Delist $ENSC and buy $ARTL.
0 · Reply
ttesty
ttesty Jan. 22 at 11:46 PM
When will $PFIZER.NSE acquire $ENSC and $ARTL?
0 · Reply
ttesty
ttesty Jan. 20 at 8:04 PM
$ARTL don't fall for $ENSC.
0 · Reply
ttesty
ttesty Jan. 20 at 8:01 PM
Meanwhile... $ARTL is up!!
0 · Reply
ttesty
ttesty Jan. 20 at 8:01 PM
Meanwhile... $ARTL is up.
0 · Reply